Assessment of blinding to treatment allocation in studies of a cannabis-based medicine (Sativex®) in people with multiple sclerosis: a new approach

Trials

Volumn 13, Issue , 2012, Pages

  Wright, Stephen ^a   Duncombe, Paul ^a   Altman, Douglas G ^b  

^a Porton Down Science Park   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Double blind; Sativex ; Treatment allocation

Indexed keywords

CANNABIS; NABIXIMOLS; PLACEBO;

APPLICATION SITE PAIN; ARTICLE; ASTHENIA; ATTENTION DISTURBANCE; BALANCE DISORDER; CENTRAL NERVOUS SYSTEM; CONSTIPATION; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DISEASE SEVERITY; DISORIENTATION; DIZZINESS; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUNK SENSATION; DYSARTHRIA; DYSGEUSIA; DYSPEPSIA; EUPHORIA; EVIDENCE BASED MEDICINE; FATIGUE; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; METHODOLOGY; MULTIPLE SCLEROSIS; NAUSEA; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SELF REPORT; SIDE EFFECT; SOMNOLENCE; SPASTICITY; TREATMENT OUTCOME; XEROSTOMIA;

BIAS (EPIDEMIOLOGY); CLINICAL TRIALS, PHASE III AS TOPIC; DOUBLE-BLIND METHOD; HUMANS; LINEAR MODELS; MARIJUANA SMOKING; MULTIPLE SCLEROSIS; MUSCLE SPASTICITY; NEUROMUSCULAR AGENTS; PLANT EXTRACTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; SELF REPORT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84867112015     PISSN: None     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/1745-6215-13-189     Document Type: Article

References (23)

1. Day SJ, Altman DG. Statistics notes: blinding in clinical trials and other studies. Br Med J 2000, 321:504.
2. Schulz KF, Chalmers I, Altman DG. The landscape and lexicon of blinding in randomized trials. Ann Intern Med 2002, 136:254-259.
3. Schulz KF, Grimes DA. Blinding in randomized trials: hiding who got what. Lancet 2002, 359:696-700. 10.1016/S0140-6736(02)07816-9, 11879884.
4. Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman DG, Gluud C, Martin R, Wood AJG, Sterne JAC. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ 2008, 336:601-605. 10.1136/bmj.39465.451748.AD, 2267990, 18316340.
5. Senn SJ. Authors have a blinkered view of blinding. BMJ 2004, 328:1135. 406364, 15130996.
6. Altman DG, Schulz KF, Moher D. Turning a blind eye. Testing the success of blinding and the CONSORT statement. BMJ 2004, 328:1135. 406364, 15130996.
7. Schulz KF, Altman DG, Moher D, Fergusson D. CONSORT 2010 changes and testing blindness in RCTs. Lancet 2010, 375:1144-1146. 10.1016/S0140-6736(10)60413-8, 20338625.
8. Sackett DL. Clinician-trialist rounds: 6. testing for blindness at the end of your trial is a mug's game. Clin Trials 2011, 8:674-676. 10.1177/1740774511419685, 22013173.
9. Wade DT, Makela P, Robson P, House H, Bateman C. Do cannabis-based medicines have general or specific effects on symptoms in MS? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler 2004, 10:434-441. 10.1191/1352458504ms1082oa, 15327042.
10. Collin C, Ehler E, Waberzinek G, AlSindi Z, Davies P, Powell K, Notcutt W, O'Leary C, Ratcliffe S, Nováková I, Zapletalova O, Piková J, Ambler Z. A double-blind, randomized, placebo-controlled parallel-group study of Sativex in subjects with symptoms of spasticity due to multiple sclerosis. Neurol Res 2010, 32:451-459. 10.1179/016164109X12590518685660, 20307378.
11. Collin C, Davies P, Mutiboko IK, Ratcliffe S. Randomised controlled trial of a cannabis-based medicine in spasticity caused by MS. Eur J Neurol 2007, 14:290-296. 10.1111/j.1468-1331.2006.01639.x, 17355549.
12. Shakespeare DT, Boggild M, Young C. Anti-spasticity agents for multiple sclerosis. Cochrane Database Syst Rev 2003, CD001332.
13. Fleuren JFM, Voerman GE, Erren-Wolters CV, Snoek GJ, Rietman JS, Hermens HJ, Nene AV. Stop using the Ashworth Scale for the assessment of spasticity. J Neurol Neurosurg Psychiatry 2010, 81:46-52. 10.1136/jnnp.2009.177071, 19770162.
14. Farrar JT, Troxel AB, Scott C, Duncombe P, Jensen MP. Validity, reliability and clinical importance of change in a 0-10 numeric rating scale measure of spasticity: a post hoc analysis of a randomized, double-blind placebo-controlled trial. Clin Ther 2008, 30:974-985. 10.1016/j.clinthera.2008.05.011, 18555944.
15. Anwar K, Barnes MP. A pilot study of a comparison between a patient scored numeric rating scale and clinician scored measures of spasticity in multiple sclerosis. NeuroRehabilitation 2009, 24:333-340.
16. Wade DT, Collin C, Stott C, Duncombe P. Meta-analysis of the efficacy and safety of Sativex (nabiximols) on spasticity in people with multiple sclerosis. Mult Scler 2010, 16:707-714. 10.1177/1352458510367462, 20558502.
17. Fergusson D, Glass KC, Waring D, Shapiro S. Turning a blind eye: the success of blinding reported in a random sample of randomized, placebo-controlled clinical trials. BMJ 2004, 328:432-437. 10.1136/bmj.37952.631667.EE, 344259, 14761905.
18. Hrobjartsson A, Forfang E, Haahr MT, Als-Nielsen B, Brorson S. Blinded trials taken to the test: an analysis of randomized clinical trials that repoprt tests for the success of blinding. Int J Epidemiol 2007, 36:654-663. 10.1093/ije/dym020, 17440024.
19. James KE, Bloch DA, Lee KK, Kraemer HC, Fuller RK. An index for assessing blindness in a multi-centre clinical trial: disulfiram for alcohol cessation - a VA cooperative study. Stat Med 1996, 15:1421-1434. 10.1002/(SICI)1097-0258(19960715)15:13<1421::AID-SIM266>3.0.CO;2-H, 8841652.
20. Bang H, Ni L, Davis CE. Assessment of blinding in clinical trials. Control Clin Trials 2004, 25:143-156. 10.1016/j.cct.2003.10.016, 15020033.
21. Zajicek J, Fox P, Sanders H, Wright D, Vickery J, Nunn A, Thompson A, . UK MS Research Group Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicenter, randomized, placebo-controlled study. Lancet 2003, 362:1517-1526. 10.1016/S0140-6736(03)14738-1, 14615106, UK MS Research Group.
22. Noseworthy JH, Ebers GC, Vandervoort MK, Farquhar RE, Yetisir E, Roberts R. The impact of blinding on the results of a randomized, placebo-controlled multiple sclerosis clinical trial. Neurology 1994, 44:16-20. 10.1212/WNL.44.1.16, 8290055.
23. Fisher RA. The principles of experiment. The Design of Experiments 1949, 11-25. Edinburgh and London: Oliver and Boyd, 5, Chapter 2.